Randomized Trialhigh evidence
Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial.
Lancet (London, England)·June 20, 2026·PMID 42259337
Why it mattersElecoglipron is an oral, once-daily small-molecule GLP-1 agonist that does not require fasting or fluid restrictions, potentially offering a more convenient alternative to injectable GLP-1 therapies for weight management in patients without diabetes.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled